Evaluation Of tuberculin skin test and booster effect in hemodialysis patients

authors:

avatar Masomeh Alimagham 1 , * , avatar Saied Aminiafshar 1 , avatar Latif Gachkar 1 , avatar Kamran Sharafim 1 , avatar Mohammad Farahbakhsh 1

Infectious Diseases and Tropical Medicine Research Center, Shaheed Beheshti University of Medical Sciences, Tehran, IR Iran

how to cite: Alimagham M, Aminiafshar S, Gachkar L, Sharafim K, Farahbakhsh M. Evaluation Of tuberculin skin test and booster effect in hemodialysis patients. Arch Clin Infect Dis. 2006;1(1): -. 

Abstract

Background:

Tuberculosis is an endemic disease in Iran which may occur more frequently among hemodialysis patients. We have evaluated tuberculin skin test (TST) in hemodialysis patients in a university hospital in 2003-2004.
Sixty-seven hemodialyis patients were enrolled for tuberculin skin tests. Indurations were measured 48-72 hours after the injection and then on the 7th day. Those with indurations less than 5mm in TST1 were introduced for TST2.

Results:

Of 67 patients, 18(26.9%) had indurations of less than 5mm in TST1 and were introduce for TST2 among whom 7 (39%) had an induration measured less than 5mm. Of 18 cases, 11 (61%) were revealed to have booster effect that represent a ratio of 16% of all studied hemodialysis patients in our study.

Conclusion:

It seems that the second TST is a better indicator of infectivity in hemodialysis patients, especially for patients who require repeated or annual estimation for M. tuberculosis infection.

Full Text

Full text is available in PDF